Eye drop trial aims to halt Diabetes-Related blindness
NCT ID NCT04505566
Summary
This study is testing if a daily anti-inflammatory eye drop (ketorolac) can slow the progression of diabetic retinopathy, a leading cause of blindness. Researchers will measure inflammatory markers in the eye and see if the eye drop reduces them and slows the disease. The study involves 164 adults with type 2 diabetes and moderate eye disease, who will use the drop or a placebo for one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.